Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSMM V Therapy Optimization Study for Multiple Myeloma
NCT00546988Phase 3Unknown
- Start
- Oct 2001
- Modality
- Stem Cell Therapies, Cytokines & Interferons, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of interferon alfa, pegylated interferon alpha, melphalan and Allogeneic Stem Cell Transplant-Alice Bertaina-acute lymphoblastic leukemia-acute myeloid leukemia-myelodysplastic syndromes-juvenile myelomonocytic leukemia-mixed phenotype acute leukemia-non-Hodgkin lymphoma-Fanconi anemia-STAT1 gain of function in multiple myeloma (MM) (4 arms). Primary endpoint: Response rate after high-dose therapy at 1 year. Status: unknown.
02
Drugs
interferon alfapegylated interferon alphamelphalanAllogeneic Stem Cell Transplant-Alice Bertaina-acute lymphoblastic leukemia-acute myeloid leukemia-myelodysplastic syndromes-juvenile myelomonocytic leukemia-mixed phenotype acute leukemia-non-Hodgkin lymphoma-Fanconi anemia-STAT1 gain of function
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00546988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546988.